LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Home・Aandelen Lijst・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

23.17 0.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.04

Max

23.25

Belangrijke statistieken
By Trading Economics
Inkomsten	675K 53M
Verkoop	1.8M 148M
K/W Sectorgemiddelde	12.608 105.69
Winstmarge	35.57
Werknemers	181
EBITDA	-3.1M 76M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+47.7% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	26M 2.6B
Vorige openingsprijs	22.3
Vorige sluitingsprijs	23.17

Nieuwssentiment

By Acuity

27%

73%

59 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

N/A / 24.28 Steun & Weerstand

Catalyst Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 nov 2025, 17:45 UTC

Winsten

Belangrijke Marktbewegers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Winsten

Belangrijke Marktbewegers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 nov 2025, 18:03 UTC

Winsten

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 nov 2025, 15:43 UTC

Winsten

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 nov 2025, 12:00 UTC

Winsten

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 nov 2025, 09:20 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Acquisities, Fusies, Overnames

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Marktinformatie

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Winsten

Acquisities, Fusies, Overnames

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Winsten

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Marktinformatie

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Acquisities, Fusies, Overnames

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Marktinformatie

Winsten

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Marktinformatie

Winsten

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Marktinformatie

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Marktinformatie

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Marktinformatie

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Marktinformatie

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Peer Vergelijking

Prijswijziging

Catalyst Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

47.7% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34 USD 47.7%

Hoogste 35 USD

Laagste 33 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Catalyst Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Catalyst Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 24.28Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

59 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.